An acid-activatable fluorouracil prodrug for colorectal cancer synergistic therapy

被引:1
作者
Ma, Xiaoqian [1 ,2 ]
Lin, Nuo [1 ,2 ]
Hu, Ke [1 ,2 ]
Xu, Chao [3 ,4 ]
Yang, Qing [1 ,2 ]
Feng, Yushuo [1 ,2 ]
Liu, Peifei [1 ,2 ]
Ding, Haizhen [1 ,2 ]
Xu, Mengjiao [1 ,2 ]
Shi, Qianqian [1 ,2 ]
Chen, Hongmin [1 ,2 ]
Xue, Fangqin [3 ,4 ]
机构
[1] Xiamen Univ, Ctr Mol Imaging & Translat Med, Sch Publ Hlth, State Key Lab Vaccines Infect Dis,Diang An Biomed, Xiamen, Peoples R China
[2] Xiamen Univ, State Key Lab Mol Vaccinol & Mol Diagnost, Natl Innovat Platform Ind Educ Intergrat Vaccine R, Xiamen, Peoples R China
[3] Fujian Med Univ, Fujian Prov Hosp, Dept Gastrointestinal Surg, Shengli Clin Med Coll, Fuzhou, Fujian, Peoples R China
[4] Fujian Prov Hosp, Clin Med Ctr Digest Dis, Fuzhou, Fujian Province, Peoples R China
基金
中国国家自然科学基金;
关键词
5-Fluorouracil; Colorectal cancer; Chemotherapy; Calcium; Oxidative stress; CALCIUM; CA2+; MITOCHONDRIAL; MECHANISMS;
D O I
10.1016/j.actbio.2024.07.012
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
5-Fluorouracil has demonstrated certain efficiency in patients with colorectal cancer. However, significant side effects of use by injection are common. To address this issue defects, a reengineered 5 '-deoxy-5-fluorocytidine (DFCR) based drug delivery system (POACa) is developed as a prominent tumor-selective nano-activator. Investigations demonstrate that the constructed nano-activator exhibits good biocompatibility and high therapeutic efficiency in mice with subcutaneous and orthotopic SW-480 colorectal tumors, as its activity is strictly dependent on the tumor-associated acid environment and thymidine phosphorylase. These strategies diminish the off-target toxicity and improve the specificity and sensitivity of human colorectal cancer cells to 5-Fu, obtaining potent efficiency by the combination of H2O2 mediated oxidative stress, calcium overload and 5-Fu-induced chemotherapy (the combination index is 0.11). Overall, the engineered nano-activator exhibits a high therapeutic index in vitro and in vivo. Statement of significance In this study, we designed and prepared a pH-responsive polymer to synchronously deliver DFCR (5 '-deoxy-5-fluorocytidine, a prodrug of 5-Fu), Ca2+ and H2O2. The constructed nano-activator was denoted as POACa. (1) To address the problem of premature leakage of cargo by physical embedding, our research modified the inactive prodrug DFCR through chemical bonding. (2) The activation of the prepared nano-activator was strictly dependent on the tumor-associated acid environment and thymidine phosphorylase, providing the drug delivery system with inherent safety. (3) A distinctly low combination index value (0.11) of CaO2 and DFCR indicated that POACa has a prominent tumor suppression effect by tumor calcium overload sensitized chemotherapy and H2O2 mediated cytotoxicity. (c) 2024 Acta Materialia Inc. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
引用
收藏
页码:350 / 360
页数:11
相关论文
共 50 条
  • [41] The role of 5-fluorouracil dose in the adjuvant therapy of colorectal cancer
    Zalcberg, JR
    Siderov, J
    Simes, J
    ANNALS OF ONCOLOGY, 1996, 7 (01) : 41 - 46
  • [42] Co-delivery systems of paclitaxel prodrug for targeted synergistic therapy of breast cancer
    Yin, Wang
    Tian, Liu
    Wang, Shenchun
    Zhang, Dezhen
    Guo, Shengrong
    Lang, Meidong
    JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2022, 69
  • [43] TREATMENT OF ADVANCED COLORECTAL-CANCER WITH FOLINIC ACID AND 5-FLUOROURACIL IN COMBINATION WITH CISPLATINUM
    SAGASTER, P
    ESSL, R
    TEICH, G
    FRITZ, E
    WASILEWSKI, M
    UMEK, H
    DUNSER, E
    MASCHER, H
    MICKSCHE, M
    EUROPEAN JOURNAL OF CANCER, 1994, 30A (09) : 1250 - 1254
  • [44] 5-FLUOROURACIL AND FOLINIC ACID IN THE TREATMENT OF ADVANCE COLORECTAL-CANCER - AN UPDATED METAANALYSIS
    BROHEE, D
    MEDICAL SCIENCE RESEARCH, 1994, 22 (05): : 383 - 384
  • [45] An injectable hydrogel for synergistic therapy in colorectal cancer by targeting glutathione
    Zhou, Jingqiu
    Jia, Dong
    Jin, Lei
    He, Wanli
    Zhang, Zhili
    Zhang, Zaishan
    Wu, Tao
    Hafeli, Urs O.
    Liu, Xu
    Han, Xue
    Wei, Shibo
    Gong, Tianxing
    CELL REPORTS PHYSICAL SCIENCE, 2025, 6 (02):
  • [46] A PHASE-II TRIAL OF 5-FLUOROURACIL, FOLINIC ACID, VINORELBINE IN PRETREATED PATIENTS WITH METASTIC COLORECTAL-CANCER
    IAFFAIOLI, RV
    FACCHINI, G
    TORTORIELLO, A
    CAPONIGRO, F
    GESUE, G
    FINIZIO, A
    DIMARTINO, N
    DESENA, G
    ANTONELLI, B
    SCARAMELLINO, G
    FEI, L
    SANTANGELO, M
    BUCCI, L
    ONCOLOGY REPORTS, 1995, 2 (04) : 513 - 516
  • [47] Multimodal enhancement of ferroptosis for synergistic cascade colorectal cancer therapy
    Wu, Ziying
    Chen, Kun
    Mo, Weisheng
    Wang, Yue
    Lin, Xiewei
    Lan, Zhien
    Mo, Caijing
    Wang, Haocheng
    Li, Xiaoying
    Fan, Xingdi
    Chen, Hungchen
    Shu, Zhilin
    Wang, Shengtao
    Yu, Zhiqiang
    Cui, Chunhui
    CHEMICAL ENGINEERING JOURNAL, 2024, 498
  • [48] Effects of 5-Fluorouracil on Oxidative Stress and Calcium Levels in the Blood of Patients with Newly Diagnosed Colorectal Cancer
    Murat Koçer
    Mustafa Nazıroğlu
    Biological Trace Element Research, 2013, 155 : 327 - 332
  • [49] RANDOMIZED COMPARISON OF FLUOROURACIL AND LEUCOVORIN THERAPY VERSUS FLUOROURACIL, LEUCOVORIN, AND CISPLATIN THERAPY IN PATIENTS WITH ADVANCED COLORECTAL-CANCER
    SCHEITHAUER, W
    DEPISCH, D
    KORNEK, G
    PIDLICH, J
    ROSEN, H
    KARALL, M
    PROCHASKA, M
    ERNST, A
    SEBESTA, C
    ECKHARDT, S
    CANCER, 1994, 73 (06) : 1562 - 1568
  • [50] CYTARABINE AND CISPLATIN AS SALVAGE THERAPY IN PATIENTS WITH METASTATIC COLORECTAL-CANCER WHO FAILED 5-FLUOROURACIL PLUS FOLINIC ACID REGIMEN
    ADENIS, A
    CARLIER, D
    DARLOY, F
    PION, JM
    BONNETERRE, J
    DEMAILLE, A
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1995, 18 (02): : 158 - 160